To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 125 participants.

Also called NCT06646354

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 125 participants (planned count) (from the registry)
Sponsor
  • Hyundai Pharm Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06646354
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06646354. Randomized; double masking; primary purpose treatment. Start 2025-04-22 (actual); primary completion 2025-05-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
Acronym
HODO-2224
Condition
Hypertension
Condition
Primary Hypercholesterolaemia
Intervention (Drug)
Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
Intervention (Drug)
Candesartan/Amlodipine
Intervention (Drug)
Candesartan/Rosuvastatin/Ezetimibe
Lead sponsor
Hyundai Pharm (class: industry)

Record details

Record id
cardio:ct-nct06646354
Content hash
556446c20c043b981ae893b49ce27df836104f5057b80f9711b996c883f27237